Viatris Inc. (VTRS) Revenue by Segment
Viatris revenue by segment at a glance
In Q2 fiscal 2026 (the quarter ended June 30, 2026), Viatris's largest business segment was Developed Markets, with $2.20 billion or 59% of revenue, up 3.4% from a year earlier. Next: Greater China (19%), Emerging Markets (14%) and Japan, Australia and New Zealand (8%).
By product or service, Brands brought in 65%, Lipitor brought in 12% and Norvasc brought in 5% of revenue in Q2 fiscal 2026.
The fastest-growing business segment from a year earlier was Greater China (+21.2%).
From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q1 fiscal 2020.
Viatris Inc.
Revenue breakdown
Fiscal quarters, from company filings
Viatris revenue by business segment, last 4 quarters
| Business segment | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Developed Markets | $2.2B | $2.0B | $2.3B | $2.1B | 59% |
| Greater China | $713.8M | $680.1M | $615.2M | $588.9M | 19% |
| Emerging Markets | $543.8M | $537.4M | $571.8M | $556.9M | 14% |
| Japan, Australia and New Zealand | $296.2M | $273.5M | $307.3M | $306.7M | 8% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Viatris revenue by product or service, last 4 quarters
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Brands | $2.4B | $2.3B | $2.4B | $2.3B | 65% |
| Lipitor | $452.2M | $462.0M | $396.1M | – | 12% |
| Norvasc | $200.2M | – | $179.7M | – | 5% |
| Lyrica | $120.6M | $120.6M | $126.5M | – | 3% |
| Viagra | $112.9M | $95.0M | – | – | 3% |
| Celebrex | $76.4M | $67.1M | $73.3M | – | 2% |
| Zoloft | $71.4M | – | $66.8M | – | 2% |
| Yupelri | $70.7M | $62.5M | $71.4M | – | 2% |
| Effexor | $66.7M | $62.0M | $67.2M | – | 2% |
| Dymista | $39.8M | $37.3M | $33.8M | – | 1% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Questions and answers
What are Viatris's business segments?
Developed Markets, Greater China, Emerging Markets and Japan, Australia and New Zealand (as reported for Q2 fiscal 2026).
Which business segment makes the most money for Viatris?
Developed Markets: $2.20 billion, or 59% of revenue, in Q2 fiscal 2026.
What are Viatris's main products and services?
By revenue in Q2 fiscal 2026: Brands (65%), Lipitor (12%), Norvasc (5%) and Lyrica (3%).
